SUMMARY We have developed a sensitive, solid phase radioimmunoassay (RIA) to quantify the amount of complement (C') fixation by anti-double-stranded DNA (anti-dsDNA) antibodies and have studied sera from 48 patients with systemic lupus erythematosus (SLE). 46% of the patients were positive in this assay. There was no correlation with serum C' levels, and only weak correlation with anti-dsDNA activity as measured by a solid phase RIA. An association was shown between positive values for C' fixation by anti-dsDNA antibodies and the presence of active lupus (p<0-01); there was a similar association with the presence of active renal disease in those patients with raised DNA binding (p<0-01). Our results suggest that quantitative measurement of C' fixation by anti-dsDNA antibodies may provide information about the pathogenicity of such antibodies in patients with SLE and be a better guide to potential end organ damage than the conventional measurement of DNA binding.
Anti-DNA antibodies have been implicated in tissue damage in SLE, though evidence as to their pathogenicity is conflicting. Particular emphasis has been placed upon the quantification of anti-dsDNA antibodies by the Farr assay. However, serum levels do not always correlate with disease activity, suggesting that pathogenicity may relate to particular properties of these antibodies.
A number of studies have investigated C' fixation by anti-DNA antibodies using antinuclear antibody (ANA) or Crithidia luciliae assays: these provide a qualitative and semiquantitative method of determining the ability of such antibodies to activate and fix C3. An ANA assay suggested a close correlation between C' fixation and the presence of nephritis.'
Crithidia luciliae assays, however, have provided conflicting evidence in this respect. [2] [3] [4] [5] There is also disagreement as to whether or not there is any correlation with the overall antibody level. [4] [5] [6] Accepted for publication 20 These methods are semiquantitative. In order to be able to measure C' fixation by anti-dsDNA antibodies in a quantitative fashion we have developed a sensitive, solid phase RIA. With this assay we have studied 48 sera from patients with SLE in order to determine the relationship between the C' fixing ability of anti-dsDNA antibodies and disease activity, the presence of active nephritis, and overall antibody levels.
Patients, materials, and methods PATIENTS Serum was taken from 48 patients who satisfied the revised American Rheumatism Association criteria for the presence of SLE.7 A clinical and laboratory assessment was made of overall disease activity. In order to distinguish between current activity of the disease and organ dysfunction due to previous damage we used critenra for determining disease activity described by Huber et al.2 Active renal disease was defined as the presence or onset within two months of proteinuria > 1 g/24 h or an active urinary sediment on microscopy. In initial studies the source of complement was used in various dilutions, and a dilution of 1/100 was shown to give the best discrimination between positive and negative sera in the assay. In a control experiment pooled normal human serum which had been decomplemented (by incubation at 56°C for 30 minutes) was used as a source of complement: no significant difference was observed between the results obtained from selected positive and negative test sera (as determined by using fresh pooled normal serum as the complement source).
The lupus sera were studied in several assays alongside sera from the 20 normal controls. Mean counts per minute (cpm) readings for the latter ranged from 2204 to 2357 (standard deviations 161 and 286 respectively) in the different assays. Readings for lupus sera ranged from 1843 to 18169 cpm. The intra-assay coefficient of variation was 7.9%.
To In Fig. 2 shows CH50 values plotted against those for C' fixation. Similarly, there was no correlation between the same variables for patients with active nephritis. Absence of correlation was maintained for the whole group of patients and for those with renal disease even when patients with DNAb values <30% were excluded. (17), lupus rash (13), neutropenia (20), lymphopenia (six), and thrombocytopenia (11) . Twenty two (46%) of the total 48 patients had a value for C' fixation > 4-6 SD above the mean of the normal controls: all of these had high overall disease activity and DNAb values >50% (Farr assay).
There was a significant association between a definitely positive value for C' fixation (>4-6 SD) and the presence of active lupus (p<0-01). Overall there was no significant association between positive C' fixation and the presence of active renal disease: however, for patients with a DNAb >30% there was a significant association (p<001).
Of the 23 patients with DNAb <80% (Fig. 2) , only two had C' fixing values > 4-6 SD and six had values >3-0 SD above the control mean; overall lupus activity in five of these patients was high. For the 15 patients with DNAb > 90%, the C' fixing values ranged from 0-8 to 98-8 SD above the control mean (median 28.4). Lupus activity was high in all of them. Eight had C' fixing values > 20 SD: six of these had active renal disease, and one developed nephritis 16 months later. The use of a solid phase RIA clearly has advantages over the Crithidia luciliae and ANA methods of detecting C' fixation by anti-dsDNA antibodies. The most important of these is that it is more fully quantitative. This has allowed us to determine the 
